Home News and Events Press Release
Press Release
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
You can learn about a more comprehensive Argo Biopharma through the latest information.
Argo Biopharma Announces First Subject Dosed in Phase I Clinical Trial of an Investigational siRNA Therapy BW-40202 Targeting Complement Factor B
Learn MoreArgo Biopharma’s Novel siRNA Therapeutic BW-20507 Granted Breakthrough Therapy Designation in China for Chronic Hepatitis B Virus Infection
Learn MoreArgo Biopharma Announces Phase 2 Advancement and Milestone Payment for siRNA Molecule BW-00163
Learn MoreArgo Biopharma to Present Promising Phase 1/2a Results of siRNA Therapeutic BW-20507 for Chronic Hepatitis B at EASL Congress 2025 (Late-Breaker)
Learn MoreArgo Biopharma to Present at the J.P. Morgan 43rd Annual Healthcare Conference
Learn MoreArgo Biopharma Announces Completion of First Participant Dosing in China Phase I Clinical Study of BW-03, a Novel RNAi Therapeutics for the Treatment of CHB
Learn MoreFirst Patient Dosed in Phase 2 Clinical Trial of Argo Biopharma BW-01, a Novel siRNA Drug for the Treatment of Severe Hypertriglyceridemia
Learn More
为了更好的呈现效果，移动端请竖屏浏览
